Knowledge Translation & Policy Analysis
After gathering information about the biomarkers of interest, we will seek to maximize the clinical and policy impact of the results of our evidence synthesis activities.
Ethics and policy analysis. Our data will be directly useful for considering what kinds of incentive, structural, or regulatory interventions could improve the use of biomarkers and the efficiency of clinical development.
The AERO-PORTAL Platform. PBRC will develop a set of user-friendly, web-based tools for producing and manipulating AERO graphs.
The PORTAL Biomarker Portal. After publication, an interactive version of our results will be available online for researchers, policymakers, regulators, and patients to examine and explore.
Conferences. A yearly invited conference will together world-renowned scientists, ethicists, and policymakers focused on discussing the implications of the work at the PBRC and identifying directions for future research.
5.1. Defining a Biomarker’s Boundary of Utility
To identify the limitations of a biomarker’s utility, elucidate the patterns of research activities by which these limitations are determined, and provide policy recommendations for how lawmakers, research funders, and regulators ought to rely on biomarkers.
5.2. Regulating an Open Science
To model the effects of various regulatory interventions on replication, validation, and efficiency of biomarker diagnostic development.
5.3 The Cost and Benefit of a Biomarker Paradigm
To provide a clear picture for how biomarker hypotheses evolve (or fail to evolve) in the face of accumulating evidence and the moral and economic burden associated with alternative thresholds for judging when a biomarker hypothesis should be considered decisively refuted or confirmed.